4th National Sero Survey of India: Vaccine Generated Antibodies Enhancement



Abstract Views
1941

Downloads
690

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Nov 5, 2021
Published Jan 19, 2022
10.24018/ejmed.2022.4.1.1132

Abstract viewed = 1941 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

The results of the fourth COVID-19 national serosurvey (June-July 2021) of India have been analysed. Much needed data of vaccine generated antibodies have been reported world first as recorded in Indian population on the ground in real. More than two-thirds of (67.6%) Indian population developed antibodies against the infection. This includes natural immunity build up due to infection and vaccine generated antibodies. Eleven states: Madhya Pradesh, Rajasthan, Bihar, Gujrat, Chhattisgarh, Uttarakhand, Uttar Pradesh, Andhra Pradesh, Karnataka, Tamil Nadu, and Odisha had sero positivity of >67.6%which was the national average. Ten other states registered < 67.6% seroprevalence were: Punjab, Telangana, Jammu and Kashmir, Himachal Pradesh, Jharkhand, West Bengal, Haryana, Maharashtra, Assam, and Kerala. Single dose vaccination of 24% population added 19% seroprevalence in the population whereas 13% full vaccination increased 28% individuals registered antibodies. The highest (90%) seroprevalence was registered among the individuals who have taken both vaccine doses followed by HCWs (85%). Seroprevalence in 85-90% population might be the threshold for herd immunity which delayed or possibly stopped the third COVID-19 wave in India.

Keywords: COVID-19 seroprevalence, fourth serosurvey, herd immunity, SARS-CoV-2 spread, serosurvey of India

Downloads

Download data is not yet available.

References

  1. Japan logs over 10,000 new COVID cases as Tokyo hits record 3,865. [Internet] [cited July 29, 2021] The Japan Times.
     Google Scholar
  2. London’s delta surge should jolt New York. [Internet] [cited July 26, 2021] The Japan Times.
     Google Scholar
  3. https://data.london.gov.uk/dataset/coronavirus-covid-19-cases.
     Google Scholar
  4. Tracking Coronavirus in New York: Latest Map and Case Count. [Internet] [cited August 2, 2021] The New York Times.
     Google Scholar
  5. Israel issues travel warning for U.S. over COVID-19 concerns. [Internet] [cited August 4, 2021] REUTERS.
     Google Scholar
  6. Our World in Data COVID-19 Vaccinations.
     Google Scholar
  7. Our World in Data COVID-19; Daily new confirmed cases per million people; United States.
     Google Scholar
  8. Covid-19 continue to rise, hospitals may run out of capacity; Bangladesh govt. [Internet] [cited July 25, 2021] Hindistan Times.
     Google Scholar
  9. Indonesia surpasses 100,000 deaths amid new virus wave. [Internet] [cited August 4, 2021] The Associated News.
     Google Scholar
  10. Worldometer-coronavirus-Indonesia.
     Google Scholar
  11. Centre asks states with high Covid caseloads to impose stricter curbs, [Internet] [cited August 1, 2021] Hindistan Times.
     Google Scholar
  12. India’s 7-day average of Covid cases crosses 40,000 again. [Internet] [cited July 31, 2021] The Times of India.
     Google Scholar
  13. After 11 weeks of decline, Covid cases see 7.5% surge. [Internet] [cited August 2, 2021] The Times of India.
     Google Scholar
  14. Why has Kerala been unable to contain Covid?, [Internet], [cited on July 31, 2021] The Times of India.
     Google Scholar
  15. https://www.worldometers.info/coronavirus/.
     Google Scholar
  16. Covid-19 antibodies last at least nine months after infection, here's how. [Internet] [cited July 20, 2021] Hindustan Times.
     Google Scholar
  17. Covid-19 infections decrease sharply among vaccinated older people. [Internet] [cited July 22, 2021] The Japan Times.
     Google Scholar
  18. German states to offer booster dose against Covid-19 to ‘vulnerable citizens. [Internet] [cited August 3, 2021] Hindustan Times.
     Google Scholar
  19. Germany issues world's strongest recommendation for mixing Covid-19 vaccines. [Internet] [cited July 2, 2021] CNN Digital Online News.
     Google Scholar
  20. Japan to lower minimum age for Moderna vaccine to 12. [Internet] [cited July 15, 2021] The Japan Times.
     Google Scholar
  21. Japan health ministry panel backs lowering Moderna vaccine age limit to 12. [Internet] [cited July 19, 2021] The Japan Times.
     Google Scholar
  22. South Korea’s Celltrion gets approval for phase 3 trials of COVID-19 antibody drug. [Internet] [cited October 12, 2021] The Asahi Shimbun.
     Google Scholar
  23. Celltrion obtains priority review in Canada for Covid-19 drug regdanvimab. [Internet] [cited August 3, 2021] Pharmaceutical Technology,
     Google Scholar
  24. Velumani A, Nikam C, Suraweera W, Fu SH, Gelband H, Brown PE, et al. SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020. medRxiv. 2021.
    DOI  |   Google Scholar
  25. Shervani Z, Bhardwaj B, Nikhat R. COVID-19 Infection in India: Seropositivity versus the Dynamics of the Spread. European Journal of Medical and Health Sciences. 2021; 3(4): 95-99.
    DOI  |   Google Scholar
  26. Shervani Z, Bhardwaj D, Sherwani A, Khan I, Qazi UY. COVID-19 Infection in 8 Big Cities of India: The Dynamics of the Spread and Seropositivity. European Journal of Medical and Health Sciences 2021; 3(6): 1-5.
    DOI  |   Google Scholar
  27. Shervani Z, Bhardwaj D, Nikhat R. Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity. European Journal of Medical and Health Sciences. 2021; 3(3): 38-41.
    DOI  |   Google Scholar
  28. Shervani Z. COVID-19 in Kerala: Health Index Theory. European Journal of Medical and Health Sciences. 2021; 3(2): 21-24.
    DOI  |   Google Scholar
  29. Shervani Z. COVID-19 in Kerala: The Dynamics of Spread and Health Index Theory. RAS Medical Science. 2021; 1(2): 1-3.
    DOI  |   Google Scholar
  30. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Viability of SARS-CoV-2 and Sanitization Methods. European Journal of Medical and Health Sciences. 2021; 3(1): 22-27.
    DOI  |   Google Scholar
  31. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Risk of SARS-CoV-2 Transmission from Humans to Pets and Vice Versa. European Journal of Medical and Health Sciences. 2021; 3(1): 34-38.
    DOI  |   Google Scholar
  32. Shervani Z, Khan I, Qazi UY. Sars-cov-2 delayed Tokyo 2020 olympics: Very recent advances in covid-19 detection, treatment, and vaccine development useful conducting the games in 2021. Advances in Infectious Diseases. 2020; 10(3): 56-66.
    DOI  |   Google Scholar
  33. Shervani Z, Khan I Qazi UY. COVID-19 vaccine. Advances in Infectious Diseases. 2020; 10(3): 195-210.
    DOI  |   Google Scholar
  34. Shervani Z, Khan I, Khan T, Qazi UY. World’s fastest supercomputer picks COVID-19 drug. Advances in Infectious Diseases. 2020; 10(3): 211-225.
    DOI  |   Google Scholar
  35. Two-third of population surveyed in 11 states has coronavirus antibodies: ICMR serosurvey. [Internet] [cited July 28, 2021] The Times of India.
     Google Scholar
  36. One in three Indians still vulnerable to COVID-19, says ICMR: findings of fourth serosurvey explained. [Internet] [cited July 22, 2021] Firstpost.
     Google Scholar
  37. Seropositivity highest in Madhya Pradesh, lowest in Kerala, finds ICMR`s national sero-survey. [Internet] [cited July 28, 2021] India Today.
     Google Scholar
  38. th Delhi sero survey shows 97% prevalence of antibodies. [Internet] [cited November 4, 2021] Hindustan Times.
     Google Scholar
  39. First phase of vaccination to start on January 16. [Internet] [cited January 9, 2021] The Hindu.
     Google Scholar


Most read articles by the same author(s)

1 2 > >>